News
Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.
3h
News-Medical.Net on MSNGLP-1 weight-loss drugs are reshaping modern dating and intimacyGLP-1 weight-loss drugs are changing how people date and connect. In a nationally representative survey of 2,000 single U.S.
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Scale AI said it’s cutting 14% of its staff weeks after Meta invested $14.3 billion in the startup and hired a number of top ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
4d
News-Medical.Net on MSNTirzepatide reduces obesity-associated breast cancer growth in mouse modelThe anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...
For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...
Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.
Staying well within their palette for the past eight decades, the team will use two versions of their traditional "Spoked B" going forward.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results